This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hohnloser, S. H. Articles by Cheuvart, B. Search for Related Content PubMed PubMed Citation Articles by Hohnloser, S. H. Articles by Cheuvart, B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Arrhythmia

(Circulation. 1995;92:1517-1525.)
© 1995 American Heart Association, Inc.

Articles

Efficacy and Safety of d-Sotalol, a Pure Class III Antiarrhythmic Compound, in Patients With Symptomatic Complex Ventricular Ectopy

Results of a Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Finding Study

Stefan H. Hohnloser, MD; Thomas Meinertz, MD; Peter Stubbs, MD; Harry J.G.M. Crijns, MD; Jean-Jacques Blanc, MD; Paolo Rizzon, MD; Brigitte Cheuvart, PhD; for the d-Sotalol PVC Study Group

From the University Hospital, Department of Cardiology, Freiburg, Germany.
¹ See "Appendix" for affiliations of authors.

Background There is increasing interest in pure class III antiarrhythmic compounds, ie, drugs in which the electrophysiological effect is confined to the propensity for producing an isolated lengthening of action potential duration. d-Sotalol represents the prototype of such pure class III agents. This double-blind, placebo-controlled, randomized dose-finding study evaluated the antiarrhythmic efficacy and safety of d-sotalol in patients with symptomatic chronic ventricular ectopy.

Methods and Results A total of 233 patients presenting with 30 premature ventricular contractions (PVCs) per hour during drug-free Holter monitoring randomly received placebo or d-sotalol at dosages of 50, 100, or 200 mg BID. Drug efficacy was assessed by repeat Holter monitoring at the end of double-blind therapy. There was a dose-dependent increase in QT and QT_c duration, indicating class III activity. A dose-related decrease in hourly PVC counts was observed, reaching statistical significance for patients receiving 200 mg d-sotalol BID (311 PVCs/h during baseline compared with 135 PVCs/h during active treatment, P<.05). Analysis of the primary efficacy criterion (ie, 75% reduction in total PVCs/h) revealed a significant treatment effect only for the highest d-sotalol dose, with 8 patients (14%) meeting this criterion. Eighteen patients reported side effects, which led to drug discontinuation in 5. One sudden death and one nonfatal cardiac arrest occurred in patients with dilative cardiomyopathy receiving 200 mg d-sotalol BID. No incidence of torsade de pointes was reported.

Conclusions d-Sotalol exerts dose-dependent class III activity in patients with symptomatic ventricular ectopy. Its PVC-suppressing activity is modest and becomes evident predominantly at dosages of 200 mg administered BID. The observation of drug-associated serious adverse arrhythmic events emphasizes the need for individualized careful dose titration, particularly in patients with advanced organic heart disease.

Key Words: tachyarrhythmias • antiarrhythmia agents • d-sotalol • ventricles • repolarization

This article has been cited by other articles:

				S. Sicouri, S. Moro, and M. V. Elizari d-Sotalol Induces Marked Action Potential Prolongation and Early Afterdepolarizations in M but Not Epicardial or Endocardial Cells of the Canine Ventricle Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(1): 27 - 37. [Abstract] [PDF]